Advances in biotechnology have brought gene therapy to the forefront of medical research. The prelude to successful gene therapy, i.e. the efficient transfer and expression of a variety of human genes into target cells, has already been accomplished in several systems. Specifically, gene regulation and targeted therapy are essential for cancer and thus gene regulation and therapeutics are a practical addition to the arsenal of approaches to many human therapies in the 21st century. This book focuses on specific gene regulation and therapeutics in various cancers and new technology used in the field, giving an overall picture to scientists and physicians who are working in cancer research.
|Publisher:||Taylor & Francis|
|Product dimensions:||6.12(w) x 9.25(h) x (d)|
About the Author
Surinder K. Batra, department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.
Moorthy Palanimuthu Ponnusamy Ph.D, department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska.
Table of Contents
KLF4 as Therapeutic Target of Inflammation and Cancer. Nuclear Factor kappa-B: Bridging Inflammation and Cancer. Exosome Based Therapeutic Targeting of Solid Malignancies. ErbB Signaling Pathway as a Goldmine for Targeted Therapy in Head and Neck Cancers. Nuclear Receptor Co-activators: Mechanism and Therapeutic Targeting in Cancer. Inflammatory Circuits as Novel Therapeutic Targets for Modulating Solid Tumor Stroma. Inflammation in Pancreatic Carcinogesis - Target for Chemoprevention of Pancreatic Cancer. Aberrant Methylation of MUC Promotors in Human Pancreatic Ductal Carcinomas. MLK3 as an Effective Therapeutic Target for Cancer. Regulation and Targeting of Zinc Transporter, ZIP4 in Pancreatic Cancer. Molecular Mediator of Prostate Cancer Progression and its Implication in Therapy. PD-L1 Deregulation and Targeting of PD-1-PD-L1 Axis in Human Cancers. Targeted Therapy for Cancer Stem Cell Population. Regulation and Targeting of MUCINs in Pancreatic Cancer. Actionable Mutations in Non-small Cell Lung Cancer.